With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.182618-86-6,1-Boc-4-(4-Nitrophenyl)piperazine,as a common compound, the synthetic route is as follows.
tert-Butyl 4-(4-nitrophenyl)piperazine-1-carboxyiate (11) (3.24 g, 10.5 mmol) was dissolved in EtOAc (90 mL) under an atmosphere of nitrogen and a slurry of 10% Pd/C (0.500 g) in EtOAc (10 mL) was added. The resulting suspension was then stirred vigorously under an atmosphere of hydrogen at room temperature for 42 hours. The catalyst was removed by filtration through Celite, which was washed with EtOAc (7 x 10 mL) and the solvent was removed in vacuo to give the title compound (12) (2.92 g, 99 % yield) as a pale pink solid; 1H N R (400 MHz, afe-DMSO) delta 6.72 – 6.66 (m, 2H), 6.52 – 6.45 (m, 2H), 4.60 (s, 2H), 3.44 – 3.39 (m, 4H), 2.87 – 2.79 (m, 4H), 1.41 (s, 9H). LCMS Method C: rt 4.40 min; m/z 278.2 [M+H]+., 182618-86-6
The synthetic route of 182618-86-6 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; CANCER THERAPEUTICS CRC PTY LTD; DEVLIN, Mark Graeme; STREET, Ian Philip; TONG, Warwick Bonner; WO2014/27199; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics